Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420784 · ClinicalTrials.gov registry record · Phase 2
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 465
- Enrollment target
NCT00420784 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 465 participants.
The verdict
NCT00420784, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 465 participants
- Enrollment target
Study Summary
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.
Interventions
- DRUG Matching Placebo
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Pegylated Interferon Alfa 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420784
The ClinicalTrials.gov registry entry for NCT00420784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Matching Placebo is the first listed.
NCT00420784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420784 about?
NCT00420784 is a clinical study titled "A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)". The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Su...
What is the current status of trial NCT00420784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 465 participants. The study started on 2007-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00420784?
The interventions under investigation include: Matching Placebo (DRUG), Ribavirin (DRUG), Telaprevir (DRUG), Pegylated Interferon Alfa 2a (DRUG).
Who is sponsoring clinical trial NCT00420784?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.